|Assessment Status||Rapid Review Complete|
|Indication||Belimumab is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.|
|Rapid review commissioned||24/04/2023|
|Rapid review completed||16/05/2023|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of belimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.